Trials / Not Yet Recruiting
Not Yet RecruitingNCT07198516
The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:
The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver: a Multicenter, Prospective, Single Arm Clinical Study
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 149 (estimated)
- Sponsor
- Fujian Medical University Union Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Addition of Hengge Liejing treatment for 48 weeks | Treatment with Hengge Liejing for 48 weeks, drug formulation: tablets. Dosage: 10mg qd, taken orally in the morning, before or after breakfast, for 48 consecutive weeks |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2026-09-01
- Completion
- 2026-12-31
- First posted
- 2025-09-30
- Last updated
- 2025-09-30
Source: ClinicalTrials.gov record NCT07198516. Inclusion in this directory is not an endorsement.